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Abstract
Background: Acute coronary syndrome (ACS) is a major cause of death from a non-communicable disease.
Secondary prevention is effective for reducing morbidity and mortality, but evidence-based targets are seldom
reached and new interventional methods are needed. The present study is a feasibility study of a telephone-based
secondary preventive programme in an unselected ACS cohort.
Methods: The NAILED (Nurse-based Age-independent Intervention to Limit Evolution of Disease) ACS trial is a
prospective randomized controlled trial. All eligible patients admitted for ACS were randomized to usual follow-up
by a general practitioner or telephone follow-up by study nurses. The intervention was made by continuous
telephone contact, with counseling on healthy living and titration of medicines to reach target values for blood
pressure and blood lipids. Exclusion criteria were limited to physical inability to follow the study design or
participation in another study.
Results: A total of 907 patients were assessed for inclusion. Of these, 661 (72.9 %) were included and randomized,
100 (11 %) declined participation, and 146 (16.1 %) were excluded. The main reasons for exclusion were
participation in another trial, dementia, and advanced disease. “Excluded” and “declining” patients were significantly
older with more co-morbidity, decreased functional status, and had more seldom received education above
compulsory school level than “included” patients. Non-participants had a higher 1-year mortality than participants.
Conclusions: Nurse-led telephone-based follow-up after ACS can be applied to a large proportion in an unselected
clinical setting. Reasons for non-participation, which were associated with increased mortality, include older age,
multiple co-morbidities, decreased functional status and low level of education.
Trial registration: International Standard Randomized Controlled Trial Number (ISRCTN): ISRCTN96595458 (archived
by WebCite at http://www.webcitation.org/6RlyhYTYK). Application date: 10 July 2011.
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Background
Survival has improved remarkably for acute cardiovascular
disease over the last few decades due to improved treat-
ment, evidence-based guidelines and effective medications
for reducing secondary morbidity. However, cardiovascu-
lar disease is still the major cause of death from a non-
communicable disease, accounting for 17.3 million deaths
annually worldwide, four million in Europe alone. The
total cost for society is estimated to be US$863 billion
worldwide and US$190 billion in Europe annually [1].
The risk of death, recurrent acute coronary syndrome
(ACS) or stroke/transitory ischemic attack (i.e., cerebro-
vascular lesion, CVL) is markedly increased after an initial
cardiac ischemic event [2]. The most important aspect for
reducing mortality after ACS is secondary preventive mea-
sures [3, 4]. To address this, evidence-based guidelines on
secondary intervention after cardiovascular disease have
been issued both nationally and internationally [5]. Med-
ical treatment alone has been shown to reduce the risk of
re-infarction and death by 20–30 % [6]. However, multiple
studies have shown that compliance to guidelines is sur-
prisingly low [7, 8] but increasing slightly [4]. In Sweden
in 2013, only 12 % of ACS patients in the SWEDEHEART
registry reached targets for the four most important pre-
ventable risk factors at follow-up (i.e., smoking, blood
pressure, low-density lipoprotein (LDL) and physical exer-
cise) [9]. In the EUROASPIRE IV survey, only one fifth of
those on lipid-lowering medication reached the target for
LDL cholesterol (<1.8 mmol/L), and less than one third
achieve targets for blood pressure, despite a high preva-
lence of modern medication use [10].
Thus, a more effective method of achieving secondary
prevention targets is needed [11]. One method, which
has proven to be cost-effective, is follow-up and medical
titration via telemedical methods [12–14]. The NAILED
(Nurse-based Age-independent Intervention to Limit
Evolution of Disease) study is an on-going randomized
controlled study on secondary preventive measures after
ACS and CVL. The aim of the NAILED study was to
evaluate whether nurse-based follow-up via telephone is
a more effective method of reaching set target values for
blood lipids and blood pressure than ordinary care by a
general practitioner (GP) [15]. The aim of this present
study was to examine the feasibility of the NAILED
protocol in ACS patients on a population basis. We
examined the rate of participation, rate and reasons for
non-participation, differences between the groups and
the 1-year mortality rate.
Methods
The overall NAILED study was designed as a non-blinded
prospective randomized controlled trial. Participants in
the present study comprised all who were considered for
inclusion in the NAILED ACS risk factor trial between 1
January 2010 and 31 January 2013. The exclusion criteria
were limited to an inability to adhere to a telephone inter-
vention and participation in another trial. The trial was
conducted at Östersund County hospital, Jämtland,
Sweden, the only hospital in the county. The hospital has
a rural catchment area of approximately 126,000 inhabi-
tants, and is where all patients with suspected ACS in the
county are sent. The ACS diagnosis was defined as myo-
cardial infarction type 1 [16], comprising ST-elevation
myocardial infarction (STEMI) and non-ST-elevation
infarction (NSTEMI) or unstable angina (UA) based on
symptoms of myocardial ischemia together with electro-
cardiographic changes (ST depression or T wave changes)
indicative of myocardial ischemia.
During in-hospital care, all patients diagnosed with
ACS were evaluated based on baseline data in interview
and medical records (i.e., clinical status, risk factors and
co-morbidities) by specially trained study nurses. Patients
eligible for inclusion at discharge were randomized to
follow-up as usual by a GP (control) or by a study nurse
(case). An extensive description of the study design for the
randomized trial is available in the study protocol [15].
Briefly, all cases were contacted by telephone 1 month
after discharge and then annually for 3 years with prior
measurements of standardized blood pressure and appro-
priate blood specimens. The cases were counseled on
compliance, smoking cessation and exercise, and their
medication titrated to reach set targets for blood pressure
and lipids. A study physician made decisions about inter-
ventions. Follow-up occurred a month after every inter-
vention, and a new titration was made if necessary.
Unscheduled appointments could be made at the patient’s
request. Controls had their standardized blood pressure
and the same blood samples taken at the same interval,
and the results were reported to their GP and the study
nurses. The aim of the overall study is to evaluate the
hypothesis that a nurse-conducted telephone-based ap-
proach to secondary prevention will lead to a significantly
larger proportion of patients reaching set targets for blood
pressure and LDL cholesterol compared to usual practice.
The following reasons for exclusion were documented:
participation in another on-going medical trial or not
being able to participate according to the study design
(i.e., not being physically or cognitively able to handle a
telephone or unable to commute to have blood samples
drawn). A 1-year follow-up of mortality was performed
in all groups for assessment. Causes of mortality were
classified based on the national Swedish National Cause
of Death Register or, if insufficient, medical records.
Kidney function was measured as estimated glomerular
filtration rate (eGFR) based on the creatinine value at
admission using the CKD-EPI formula. Every patient’s
functional status was assessed according to the modified
Rankin scale (mRS) by the study nurses.
Huber et al. Trials  (2016) 17:85 Page 2 of 8
Statistical analyses were performed with IBM SPSS
statistics software v 22.
All patients, or their next of kin, gave verbal informed
consent to the collection of baseline data and the study
was approved by the Regional Ethical Review Board,
Umeå University, Umeå, Sweden (16/12/2009, ref: Dnr
09-142 M; 10/06/2013, ref: Dnr 2013-204-32 M).
Statistical analysis
Patients were subdivided into the following categories:
“included” (eligible for inclusion and willing to participate),
“declined” (eligible for inclusion but not willing to partici-
pate) and “excluded” (not eligible for inclusion). We com-
pared basic characteristics and variables of interest
between the three groups with two-sided chi2 tests,
Fischer’s exact test or independent samples t test as appro-
priate. A p value <0.05 was considered significant.
To identify independent predictors of the decision to
not participate, we set up a multivariate logistic regression
model of variables with an alpha level <0.1 in the univari-
ate analyses between the “included” and “declined” groups.
We then performed manual stepwise exclusion based on
the level of significance. To evaluate independent baseline
characteristics important for exclusion, we set up a second
multivariate model between included and excluded
patients in the same manner. Sex and age were included
in both regression models regardless of statistical signifi-
cance. The results are presented as odds ratios (ORs) with
95 % confidence intervals (CIs). We categorized continu-
ous variables in the multivariate models.
To assess 1-year cumulative survival we made
Kaplan-Meier estimations with group comparisons
using the log rank test. To calculate ORs for mortality, we
used univariate logistic regression.
Results
During the inclusion period, 961 patients were hospital-
ized with ACS and primarily assessed. Fifty-four patients
died during hospitalization. Of the remaining 907 patients,
249 (27.5 %) were diagnosed with STEMI, 589 (64.9 %)
with NSTEMI, and 69 (7.6 %) with unstable angina (UA).
After assessment, 661 (73 %) were randomized into the
study, 146 (16 %) were excluded, and 100 (11 %) declined
participation (Fig. 1). The most common cause for exclu-
sion was participation in another trial (29 %, 43/146),
followed by dementia (25 %, 37/146) and advanced disease
other than cardiac disease or stroke (24 %, 35/146). Taking
into account the eligible patients excluded because of
participation in another trial, the “excluded” group would
decrease to 103 patients (11 %).
Baseline patient characteristics are presented in Table 1.
In a univariate comparison between the “included” and
“excluded” subgroups, we found that the “excluded” group
consisted of significantly older patients and a larger
proportion with a mRS score >3. The “excluded” group
had a larger proportion of women and a lower proportion
of patients with an education above compulsory school
level. Excluded patients had a lower body mass index
(BMI), decreased kidney function, and a larger proportion
with previous ischemic heart disease (IHD), congestive
Fig. 1 Study flow chart
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heart failure (CHF), stroke and peripheral arterial disease.
The “included” group also had fewer patients with atrial
fibrillation, prior hypertension or diabetes. No variables
were missing more than 3 % data except “known hyperlip-
idemia” (missing 25.6 % of data) which, therefore, was
excluded from all further analyses.
Patients who declined participation had significantly
different baseline characteristics than “included”
patients. Declining patients were generally older with a
larger proportion being women and patients with mRS
>3, and a larger proportion lacked education above com-
pulsory school level. Also, the eGFR was lower in the
“declining” group. Regarding established risk factors, a
larger proportion of patients in the group that declined
participation had previous cerebrovascular disease, con-
gestive heart failure CHF and atrial fibrillation. Patients
who declined participation differed from excluded pa-
tients only in regards to a lower proportion with a mRS
score >3 or education above compulsory school level,
but these differences were not significant.
In the first multivariate analysis, female sex, mRS >3,
education limited to compulsory school level and age
85 years or older were significantly associated with a
decision to decline participation (Fig. 2). In the second
multivariate model, age 85 years or older, mRS >3 and
known congestive heart failure CHF were associated
with exclusion (Fig. 2). During the first year after dis-
charge, 88 (9.7 %) patients died: 43 in the “included” group
Table 1 Patient characteristics
Included Excluded Declined p p p
N % or SD n % or SD n % or SD i/e i/d d/e
Subjects 661 72.9 146 16.1 100 11
Gender (male) 453 68.5 80 54.8 47 53 0.002 <0.001 0.230
Mean age (years ± SD) 69.2 ± 11.9 76.3 ± 12.1 77.3 ± 11.7 <0.001 <0.001 0.499
Basic characteristics
mRS >3 7 1.1 33 22.6 8 8.0 <0.001 <0.001 0.003
eGFR 78.4 ± 21.3 68.9 ± 22.9 70.4 ± 21.5 <0.001 0.001 0.597
eGFR <60 128 19.4 52 35.6 29 29 <0.001 0.026 0.278
eGFR 60–90 308 46.6 66 45.2 50 50 0.76 0.525 0.459
eGFR >90 225 34.0 28 19.2 21 21 <0.001 0.009 0.725
BMI (mean ± SD) 27.3 ± 4.5 25.8 ± 5.2 26.4 ± 5 0.001 0.077 0.375
BMI <18.5 5 ± 0.8 14 ± 10.1 3 ± 3.1 <0.001 0.070 0.044
BMI 18.5–25 206 ± 31.2 49 ± 35.3 34 ± 35.1 0.347 0.442 0.975
BMI 25–30 295 ± 44.6 53 ± 38.1 39 ± 40.2 0.160 0.413 0.748
BMI >30 155 ± 23.4 23 ± 16.5 21 ± 21.6 0.075 0.695 0.322
Only basic education 345 52.2 99 67.8 77 77.0 <0.001 <0.001 0.231
Heredity (first line) 178 27.3 28 21.5 20 21.5 0.173 0.237 0.995
Previous morbidities
Previous IHD 156 23.6 51 34.9 34 34.0 0.005 0.025 0.880
Current NSTEMI 420 63.5 100 68.5 69 69.0 0.258 0.288 0.933
Current STEMI 182 27.5 42 28.8 25 25.0 0.763 0.596 0.514
Previous stroke 48 7.3 26 17.8 15 15.0 <0.001 0.009 0.562
Peripheral artery disease 15 2.3 8 5.5 5 5.0 0.035 0.112 0.869
Congestive heart failure CHF (Previous) 23 3.5 20 13.7 10 10.0 <0.001 0.003 0.384
Smoking (current/previous) 414 62.6 79 54.1 57 57.0 0.065 0.272 0.697
Atrial fibrillation 95 14.8 42 29.4 26 26.0 <0.001 0.002 0.701
Hyperlipidemia 463 96.1 110 96.5 80 100 0.829 0.071 0.090
Hypertension 354 53.6 95 65.1 67 67.0 0.011 0.012 0.754
Diabetes 135 20.4 45 30.8 28 28.0 0.006 0.085 0.634
p values for comparison: i/e, included versus excluded; i/d, included versus declined; d/e, declined versus excluded. Hyperlipidemia: treatment initiated or
untreated total cholesterol >4.5 mmol/L or untreated LDL cholesterol >2.5 mmol/L
BMI body mass index, eGFR estimated glomerular filtration rate, IHD ischemic heart disease, LDL low-density lipoprotein, mRS modified Rankin scale, NSTEMI non-
ST-elevation myocardial infarction, SD standard deviation, STEMI ST-elevation myocardial infarction
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(6.5 %), 29 in the “excluded” group (19.9 %) and 16 in the
“declining” group (16 %). Regarding the 1-year mortality
prognosis, we found a significant difference between the
“included” group and the “excluded” and “declining”
groups (p <0.001, Fig. 3). The cumulative survival was not
significantly different (p = 0.21) between the “excluded”
and “declining” groups. However, the Kaplan-Meier curves
revealed increased mortality during the first few months
for the “excluded” group. Cardiovascular reasons were an
insignificantly more common cause of death (52.1 % ver-
sus 47.9 %) than non-cardiovascular reasons in the overall
population.
Discussion
This study was a non-participation feasibility study of a
telemedical method to improve adherence to secondary
preventive measures after a coronary ischemic event.
Almost three quarters of admitted patients were eligible
for inclusion in our community-based rural cohort. The
main reasons for non-participation were declining by
one’s own will, participation in another medical trial,
dementia and severe cardiovascular disease.
In univariate analyses, factors that indicated a larger
proportion of co-morbidity (decreased eGFR and BMI
and previous heart disease or CVL) were significant for
non-participation and a disadvantage for women. We
can only speculate about the result for women, but our
subanalyses showed a significantly lower level of education
among women compared to men (data not shown). Low
education is considered a measure of socioeconomic sta-
tus (SES) and known to increase cardiovascular risk [17].
Our study showed a significant increase in 1-year
mortality for non-participants. Since the groups are
selected as shown in Table 1, the mortality analysis is
only descriptive and illustrates the high early mortality in
non-participants. Subjective reasons for declining partici-
pation are multifaceted. We tried to objectify these rea-
sons using a multivariate regression model of quantifiable
surrogate variables. This analysis showed that the main
variables for the decision to decline were older age,
increased disability as measured in mRS, and education
limited to compulsory school level. Predictors of exclusion
in the second multivariate regression model were older
age, reduced autonomy in mRS and congestive heart
failure CHF. Notably, the “excluded” and “declined”
groups only differed in terms of autonomy (mRS >3) at
univariate comparison.
Reducing the burden of modifiable risk factors is an
important goal for both individuals and society. There-
fore, a standardized and cost-effective programme that
Fig. 2 a Multivariate association with decision to decline participation. b With exclusion. Age 65 years or under was used as a reference category
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can be applied to a large proportion of patients in both
urban and rural settings is needed. We designed the
NAILED study without predefined exclusion criteria
except participation in another trial or inability to
adhere to the concept of a telephone intervention. We
intended to mimic a natural cohort and clinical setting
as much as possible. We found that a simple follow-up
method made it possible to include a large proportion of
an unselected population-based ACS cohort.
To the best of our knowledge, this is the first study of
the implementation of a multifactorial secondary prevent-
ive programme at the population level. Other studies on
telephone-based secondary prevention programmes are
restricted in terms of more extensive inclusion or
exclusion criteria, age or small selected population
samples [12, 18]. Consequently, direct comparisons re-
garding rates of participation and mortality are difficult.
A dilemma with existing secondary preventive pro-
grammes is that they tend to be more accessible to
patients with higher income and education. The
PURE study concluded that, even though high-income
countries have the highest prevalence of cardiovascu-
lar risk factors, mortality is lower than in low-income
countries due to less effective healthcare in the latter
[19, 20]. In a study by Bergström et al., prognosis
after AMI worsened with lower SES despite a state-
funded healthcare system with a strong egalitarian
tradition and after adjusting for traditional risk factors
[21]. Jelinek et al. showed that individual coaching via
telephone reduced inequalities in secondary preventive
target fulfillment due to social class [22]. Eighteen
months after the intervention, the effects were sus-
tained [23].
The present study was conducted in a rural setting in
Sweden. However, the present secondary prevention
programme can be implemented in both urban and rural
settings in large parts of the world as much of the inter-
vention was by telephone with little demand for travel.
Intervening health workers need only basic training and
access to a consulting physician.
It is important that a secondary prevention strategy is
designed so that all inhabitants can take part, regardless
of age and co-morbidities. The NAILED protocol was
constructed to be as including and comprehensive as
possible. Because low education and reduced autonomy
were independent factors for a patient’s unwillingness to
participate, we speculate on the presence of an increased
need for education at discharge in these groups. The
older aged and advanced disease group is more challen-
ging, but studies indicate low adverse effects from
secondary preventive interventions and potential
benefits on morbidity, but various effects on mortality
[24, 25]. Further studies need to be conducted to eluci-
date with what means we can reach our oldest patients
with multi-morbidity. It would also be important to
identify settings in which preventive efforts are futile.
Fig. 3 One-year survival Kaplan-Meier estimates and group comparison. Odds ratio (OR) for mortality. p/np participant/non-participant, i included,
e excluded, d declined
Huber et al. Trials  (2016) 17:85 Page 6 of 8
Strengths and limitations
A strength of this study is that the cohort consists of an
unselected cardiovascular population. Only one hospital
is in the catchment area, which gives us a good overview
of the cohort and local treatment traditions. During an
initial 3-month control period, no missed cases were
found. A weakness is that this is a single center study
and general applicability may be questioned. We also
lack variables to extensively evaluate SES. Additionally,
patients not referred to the cardiology department, prob-
ably due to clinicians regarding interventions as more
harmful than useful in the specific patient’s circum-
stances, could have been missed despite the study nurses
surveying all departments outside the cardiac care unit.
Conclusion
Nurse-led telephone-based follow-up of secondary
prevention after coronary ischemic events can be applied
to a large proportion of patients in an unselected clinical
setting. Increased mortality is seen in those who do not
participate. Reasons for non-participation include older
age, multiple co-morbidities, decreased functional status
and education limited to compulsory school level.
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